RTI Hoping FDA Review Can Lead To Regeneration In 2002
This article was originally published in The Gray Sheet
Executive Summary
Regeneration Technologies, Inc. says it will reclassify "certain expenses" from prior financial reports but will not have to restate any previously reported results